Page last updated: 2024-08-26

yttrium radioisotopes and Cancer of Prostate

yttrium radioisotopes has been researched along with Cancer of Prostate in 41 studies

Research

Studies (41)

Timeframe	Studies, this research(%)	All Research%
pre-1990	7 (17.07)	18.7374
1990's	4 (9.76)	18.2507
2000's	20 (48.78)	29.6817
2010's	7 (17.07)	24.3611
2020's	3 (7.32)	2.80

Authors

Authors	Studies
Ahrens, M; Bauer, S; Fendler, WP; Ferdinandus, J; Fragoso Costa, P; Hamacher, R; Herrmann, K; Kessler, L; Kostbade, K; Lippert, M; Lueckerath, K; Mavroeidi, IA; Pabst, KM; Rischpler, C; Schuler, M; Siveke, JT; Umutlu, L; Weber, M	1
Bailey, KL; Burks, M; Casalino, D; Dreher, MR; Gates, VL; Gordon, AC; Harris, K; Hohlastos, E; Khan, A; Kim, DH; Lewandowski, RJ; Li, W; Manupipatpong, S; Matsumoto, M; Miller, FH; Mouli, SK; Mylarapu, A; Pasciak, AS; Raiter, S; Salem, R; Weiss, CR	1
Albisinni, S; Aoun, F; Mjaess, G; Roumeguère, T	1
Hsu, MJ; Padia, SA; Srinivasa, RN; Tran, DN	1
Ding, N; Kanada, Y; Kanazaki, K; Ono, M; Saji, H; Sano, K	1
Chen, X; Jacobson, O; Kiesewetter, DO; Lang, L; Ma, Y; Niu, G; Szajek, LP; Tian, R; Wang, Z	1
Amato, E; Botta, F; Cremonesi, M; Ferrari, ME; Guerriero, F; Paganelli, G; Pedroli, G; Sarnelli, A; Severi, S; Vavassori, A	1
Buckway, B; Frazier, N; Ghandehari, H; Gormley, AJ; Ray, A	1
Alicke, B; Heitner, T; Lewis, JS; Light, DR; McLean, K; Parry, G; Parry, R; Satozawa, N; Schneider, DW; Yoo, J	1
Bander, NH; Farokhzad, OC; Gu, FX; Huynh-Le, M; Kantoff, PW; Langer, R; Radovic-Moreno, AF; Wang, AZ; Yuet, K; Zhang, L	1
Hanna, M; Mikko, T	1
FERGUSSON, JD	1
IRONSIDE, WM; MOSELEY, RD	1
FESANI, F; GOFFRINI, P; PERACCHIA, A	1
GREENE, WM	1
DeNardo, GL; DeNardo, SJ; Jacobs, F; Kukis, DL; Lamborn, KR; Lara, PN; Natarajan, A; O'Donnell, RT; Richman, CM; Siantar, CL; Yuan, A	1
Bander, NH; Goldsmith, SJ; Kostakoglu, L; Milowsky, MI; Nanus, DM; Vallabahajosula, S	1
Bander, NH; Goldsmith, SJ; Navarro, V; Smith-Jones, PM; Vallabhajosula, S	1
Bander, NH; Goldsmith, SJ; Kostakoglu, L; Milowsky, MI; Nanus, DM; Vallabhajosula, S	2
Chen, J; Hinni, K; Maecke, HR; Reubi, JC; Waldherr, C; Waser, B; Zhang, H	1
Bander, N; Bastidas, D; Goldsmith, S; Hamacher, K; Konishi, S; Kothari, P; Vallabhajosula, S	1
Hsieh, FY; Law, SJ; Lu, SX; Solomon, M; Takach, EJ; Zhu, Q	1
Bander, NH; Goldsmith, SJ; Hamacher, KA; Konishi, S; Kostakoglu, L; Kothari, PA; Kuji, I; Milowski, MI; Nanus, DM; Vallabhajosula, S	1
Scott, AM	1
Bander, NH; Goldsmith, SJ; Hamacher, KA; Konishi, S; Kostakoglu, L; Milowski, MI; Nanus, DM; Vallabhajosula, S	1
Al Hashmi, D; Baithun, S; Britton, KE; Carroll, M; Ellison, D; Gordon, S; Kumar, P; Nargund, V; Otitie, U	1
Chew, HK; DeNardo, GL; Denardo, SJ; Goldstein, DS; Kukis, DL; Lamborn, KR; Lara, PN; Meares, CF; Natarajan, A; O'Donnell, RT; Richman, CM; Shen, S; Tuscano, JM; Wun, T; Yuan, A	1
Alicke, B; Biroc, S; Bringmann, P; Cobb, RR; Dinter, H; Halks-Miller, M; Harkins, R; Hudson, D; Klocker, H; Kretschmer, PJ; Larsen, B; Lewis, JS; Lin, R; Newton, A; Parkes, D; Parry, G; Parry, R; Roth, G; Schneider, D; Toy, P; Xuan, JA; Zhu, Y	1
Albrecht, H; Burke, PA; DeNardo, GL; DeNardo, SJ; Gregg, JP; Natarajan, A; O'Donnell, RT; Richman, CM; Yuan, A	1
Ghandehari, H; Line, BR; Mitra, A; Nan, A; Papadimitriou, JC	1
DeNardo, GL; DeNardo, SJ; Lehmann, J; O'Donnell, RT; Richman, CM; Shen, S; Yuan, A	1
Becker, M; Brod, KH; Dähnert, W; Grimm, W; Kutzner, J; Schreyer, T	1
Hammer, J	1
Braun, U; Herzog, H; Müller-Gärtner, HW; Neumaier, B; Plag, C; Rösch, F; Stöcklin, G	1
Angelberger, P; Bischof, C; Gludovacz, D; Hamilton, G; Kaserer, K; Kofler, A; Leimer, M; Pangerl, T; Peck-Radosavljevic, M; Schlangbauer-Wadl, H; Smith-Jones, PM; Traub, T; Virgolini, I	1
Austin, JC; Gerstbrein, J; Kahn, D; Maguire, RT; Miller, SJ; Williams, RD	1
DeNardo, GL; DeNardo, SJ; Kukis, DL; Lamborn, KR; Meyers, FJ; Miers, L; O'Donnell, RT	1
DeNardo, GL; DeNardo, SJ; Goldstein, DS; Griffith, IJ; Kukis, DL; Lara, PN; Martinez, GS; Meyers, FJ; Mirick, GR; O'Donnell, RT; Richman, CM; Shen, S; Yuan, A	1
Lee, KJ	1
Beyer, GJ; Bockisch, A; Grimm, W; Hahn, K; Kutzner, J; Rösler, HP	1

Reviews

2 review(s) available for yttrium radioisotopes and Cancer of Prostate

Article	Year
Antibodies targeting Prostate-Specific Membrane Antigen positive prostate cancer: from diagnostic imaging to theranostics. Current opinion in oncology, 2021, 09-01, Volume: 33, Issue:5 Topics: Actinium; Humans; Male; Positron Emission Tomography Computed Tomography; Precision Medicine; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms; Yttrium Radioisotopes	2021
Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen. Seminars in oncology, 2003, Volume: 30, Issue:5 Topics: Animals; Antibodies, Monoclonal; Antibody Affinity; Antigens, Surface; Clinical Trials, Phase I as Topic; Cytotoxins; Disease Models, Animal; Drug Delivery Systems; Drug Evaluation, Preclinical; Extracellular Space; Fluorescent Antibody Technique; Glutamate Carboxypeptidase II; Humans; Immunoglobulin G; Lutetium; Male; Mice; Prostatic Neoplasms; Radioimmunodetection; Radioisotopes; Treatment Outcome; Yttrium Radioisotopes	2003

Article

Year

Antibodies targeting Prostate-Specific Membrane Antigen positive prostate cancer: from diagnostic imaging to theranostics.

Current opinion in oncology, 2021, 09-01, Volume: 33, Issue:5

Topics: Actinium; Humans; Male; Positron Emission Tomography Computed Tomography; Precision Medicine; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms; Yttrium Radioisotopes

2021

Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen.

Seminars in oncology, 2003, Volume: 30, Issue:5

Topics: Animals; Antibodies, Monoclonal; Antibody Affinity; Antigens, Surface; Clinical Trials, Phase I as Topic; Cytotoxins; Disease Models, Animal; Drug Delivery Systems; Drug Evaluation, Preclinical; Extracellular Space; Fluorescent Antibody Technique; Glutamate Carboxypeptidase II; Humans; Immunoglobulin G; Lutetium; Male; Mice; Prostatic Neoplasms; Radioimmunodetection; Radioisotopes; Treatment Outcome; Yttrium Radioisotopes

2003

Trials

7 trial(s) available for yttrium radioisotopes and Cancer of Prostate

Article	Year
Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jul-01, Volume: 22, Issue:13 Topics: Aged; Aged, 80 and over; Androgens; Antibodies, Monoclonal; Antigens, Surface; Disease Progression; Drug Resistance, Neoplasm; Glutamate Carboxypeptidase II; Humans; Male; Maximum Tolerated Dose; Middle Aged; Prostatic Neoplasms; Radionuclide Imaging; Yttrium Radioisotopes	2004
Pharmacokinetics and biodistribution of 111In- and 177Lu-labeled J591 antibody specific for prostate-specific membrane antigen: prediction of 90Y-J591 radiation dosimetry based on 111In or 177Lu? Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2005, Volume: 46, Issue:4 Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Body Burden; Half-Life; Humans; Indium Radioisotopes; Lutetium; Male; Metabolic Clearance Rate; Middle Aged; Organ Specificity; Prostate-Specific Antigen; Prostatic Neoplasms; Radioisotopes; Radiometry; Radiopharmaceuticals; Radiotherapy Dosage; Relative Biological Effectiveness; Tissue Distribution; Yttrium Radioisotopes	2005
Prediction of myelotoxicity based on bone marrow radiation-absorbed dose: radioimmunotherapy studies using 90Y- and 177Lu-labeled J591 antibodies specific for prostate-specific membrane antigen. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2005, Volume: 46, Issue:5 Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Body Burden; Bone Marrow; Bone Marrow Diseases; Dose-Response Relationship, Radiation; Humans; Lutetium; Male; Maximum Tolerated Dose; Middle Aged; Organ Specificity; Prostate-Specific Antigen; Prostatic Neoplasms; Radiation Injuries; Radioimmunotherapy; Radioisotopes; Radiotherapy Dosage; Relative Biological Effectiveness; Yttrium Radioisotopes	2005
High-dose radioimmunotherapy combined with fixed, low-dose paclitaxel in metastatic prostate and breast cancer by using a MUC-1 monoclonal antibody, m170, linked to indium-111/yttrium-90 via a cathepsin cleavable linker with cyclosporine to prevent human Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Aug-15, Volume: 11, Issue:16 Topics: Adult; Aged; Aged, 80 and over; Animals; Antibodies, Monoclonal; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Breast Neoplasms; Cathepsins; Combined Modality Therapy; Cyclosporine; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Female; Heterocyclic Compounds, 1-Ring; Humans; Indium Radioisotopes; Male; Mice; Middle Aged; Neutropenia; Paclitaxel; Prostatic Neoplasms; Radioimmunotherapy; Soft Tissue Neoplasms; Treatment Outcome; Yttrium Radioisotopes	2005
Radioimmunotherapy of prostate cancer using 90Y- and 177Lu-labeled J591 monoclonal antibodies: effect of multiple treatments on myelotoxicity. Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Oct-01, Volume: 11, Issue:19 Pt 2 Topics: Antibodies, Monoclonal; Blood Platelets; Bone Marrow; Dose Fractionation, Radiation; Follow-Up Studies; Humans; Lutetium; Male; Maximum Tolerated Dose; Prostate-Specific Antigen; Prostatic Neoplasms; Radioimmunotherapy; Radioisotopes; Thrombocytopenia; Time Factors; Yttrium Radioisotopes	2005
A phase II study of [90Y] yttrium-capromab pendetide in the treatment of men with prostate cancer recurrence following radical prostatectomy. Cancer biotherapy & radiopharmaceuticals, 1999, Volume: 14, Issue:2 Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Bone Marrow; Combined Modality Therapy; Edetic Acid; Gonadotropin-Releasing Hormone; Humans; Immunoconjugates; Leukopenia; Male; Middle Aged; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Radiation Injuries; Radioimmunodetection; Salvage Therapy; Soft Tissue Neoplasms; Thrombocytopenia; Tissue Distribution; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; Treatment Failure; Treatment Outcome; Yttrium Radioisotopes	1999
Radioimmunotherapy with (111)In/(90)Y-2IT-BAD-m170 for metastatic prostate cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2001, Volume: 7, Issue:6 Topics: Adenocarcinoma; Aged; Animals; Antibodies, Monoclonal; Cohort Studies; Combined Modality Therapy; Humans; Indium Radioisotopes; Male; Mice; Middle Aged; Neoplasm Metastasis; Pain; Prostate-Specific Antigen; Prostatic Neoplasms; Radioimmunotherapy; Radiometry; Time Factors; Treatment Outcome; Yttrium Radioisotopes	2001

Other Studies

32 other study(ies) available for yttrium radioisotopes and Cancer of Prostate

Article	Year
Safety and Efficacy of 90Y-FAPI-46 Radioligand Therapy in Patients with Advanced Sarcoma and Other Cancer Entities. Clinical cancer research : an official journal of the American Association for Cancer Research, 2022, 10-03, Volume: 28, Issue:19 Topics: Humans; Male; Pancreatic Neoplasms; Prostatic Neoplasms; Quinolines; Sarcoma; Yttrium Radioisotopes	2022
Yttrium-90 Radioembolization to the Prostate Gland: Proof of Concept in a Canine Model and Clinical Translation. Journal of vascular and interventional radiology : JVIR, 2021, Volume: 32, Issue:8 Topics: Animals; Brachytherapy; Dogs; Embolization, Therapeutic; Humans; Male; Prostate; Prostatic Neoplasms; Yttrium Radioisotopes	2021
Transsplenic Arterial Radioembolization of Hepatic Metastases in a Patient with Celiac Artery Occlusion. Journal of vascular and interventional radiology : JVIR, 2019, Volume: 30, Issue:10 Topics: Aged; Arterial Occlusive Diseases; Catheterization, Peripheral; Celiac Artery; Constriction, Pathologic; Embolization, Therapeutic; Humans; Liver Neoplasms; Male; Prostatic Neoplasms; Radiography, Interventional; Radiopharmaceuticals; Splenic Artery; Treatment Outcome; Yttrium Radioisotopes	2019
Brachytherapy with Intratumoral Injections of Radiometal-Labeled Polymers That Thermoresponsively Self-Aggregate in Tumor Tissues. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2017, Volume: 58, Issue:9 Topics: Animals; Brachytherapy; Cell Line, Tumor; Indium Radioisotopes; Injections, Intralesional; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Oxazoles; Polymerization; Prostatic Neoplasms; Radiopharmaceuticals; Temperature; Tissue Distribution; Yttrium Radioisotopes	2017
Single Low-Dose Injection of Evans Blue Modified PSMA-617 Radioligand Therapy Eliminates Prostate-Specific Membrane Antigen Positive Tumors. Bioconjugate chemistry, 2018, 09-19, Volume: 29, Issue:9 Topics: Animals; Dipeptides; Evans Blue; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Mice; Positron-Emission Tomography; Prostate-Specific Antigen; Prostatic Neoplasms; Radiopharmaceuticals; Xenograft Model Antitumor Assays; Yttrium Radioisotopes	2018
Investigation of 90Y-avidin for prostate cancer brachytherapy: a dosimetric model for a phase I-II clinical study. European journal of nuclear medicine and molecular imaging, 2013, Volume: 40, Issue:7 Topics: Avidin; Brachytherapy; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Feasibility Studies; Humans; Male; Models, Biological; Prostatic Neoplasms; Radiometry; Yttrium Radioisotopes	2013
Gold nanorod-mediated hyperthermia enhances the efficacy of HPMA copolymer-90Y conjugates in treatment of prostate tumors. Nuclear medicine and biology, 2014, Volume: 41, Issue:3 Topics: Acrylamides; Animals; Cell Line, Tumor; Female; Gold; Heterocyclic Compounds, 1-Ring; Humans; Hyperthermia, Induced; Male; Mice; Nanotubes; Prostatic Neoplasms; Tomography, Emission-Computed, Single-Photon; Yttrium Radioisotopes	2014
In vivo biodistribution, PET imaging, and tumor accumulation of 86Y- and 111In-antimindin/RG-1, engineered antibody fragments in LNCaP tumor-bearing nude mice. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2009, Volume: 50, Issue:3 Topics: Animals; Antibodies, Monoclonal; Cell Line, Tumor; Chelating Agents; Humans; Indium Radioisotopes; Isothiocyanates; Male; Mice; Mice, Nude; Neoplasm Transplantation; Pentetic Acid; Positron-Emission Tomography; Prostatic Neoplasms; Radiopharmaceuticals; Tissue Distribution; Tomography, X-Ray Computed; Transplantation, Heterologous; Yttrium Radioisotopes	2009
ChemoRad nanoparticles: a novel multifunctional nanoparticle platform for targeted delivery of concurrent chemoradiation. Nanomedicine (London, England), 2010, Volume: 5, Issue:3 Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Combined Modality Therapy; Docetaxel; Humans; Indium Radioisotopes; Male; Nanoparticles; Prostatic Neoplasms; Taxoids; Yttrium Radioisotopes	2010
[Radionuclide therapy for cancer--what's new?]. Duodecim; laaketieteellinen aikakauskirja, 2012, Volume: 128, Issue:21 Topics: Embolization, Therapeutic; Female; Finland; Humans; Iodine Radioisotopes; Liver Neoplasms; Male; Neoplasms; Neuroendocrine Tumors; Octreotide; Paraganglioma; Pheochromocytoma; Prostatic Neoplasms; Radiotherapy; Thyroid Neoplasms; Yttrium Radioisotopes	2012
Implantation of radioactive material into the pituitary for the control of prostatic cancer: an interim review. British journal of urology, 1957, Volume: 29, Issue:3 Topics: Humans; Male; Pituitary Diseases; Pituitary Gland; Prostatic Neoplasms; Radioactivity; Yttrium; Yttrium Radioisotopes	1957
Pernasal transsphenoidal yttrium implant of the hypophysis. Postgraduate medicine, 1958, Volume: 24, Issue:5 Topics: Breast Neoplasms; Humans; Male; Pituitary Gland; Prostatic Neoplasms; Prostheses and Implants; Yttrium; Yttrium Radioisotopes	1958
[Implantation of radioactive yttrium (Y90) in the sella turcica in the treatment of breast and prostate carcinoma in the advanced stage (considerations on 21 cases)]. Archivio italiano di chirurgia, 1959, Volume: 85 Topics: Breast; Breast Neoplasms; Humans; Hypophysectomy; Male; Neoplasms; Prostatic Neoplasms; Sella Turcica; Yttrium; Yttrium Radioisotopes	1959
EMBOLIZATION OF DOG PROSTATES WITH YTTRIUM-90 MICROSPHERES. The Journal of urology, 1963, Volume: 90 Topics: Dogs; Embolism; Embolization, Therapeutic; Humans; Male; Microspheres; Neoplasms; Prostatic Neoplasms; Radiation Protection; Research; Yttrium; Yttrium Radioisotopes	1963
Enhanced therapeutic index of radioimmunotherapy (RIT) in prostate cancer patients: comparison of radiation dosimetry for 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid (DOTA)-peptide versus 2IT-DOTA monoclonal antibody linkage for RIT. Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Sep-01, Volume: 9, Issue:10 Pt 2 Topics: Antibodies, Monoclonal; Chelating Agents; Heterocyclic Compounds, 1-Ring; Humans; Indium Radioisotopes; Male; Models, Chemical; Peptides; Prostatic Neoplasms; Radioimmunotherapy; Radiometry; Radiopharmaceuticals; Time Factors; Tissue Distribution; Treatment Outcome; Yttrium Radioisotopes	2003
Radioimmunotherapy of prostate cancer in human xenografts using monoclonal antibodies specific to prostate specific membrane antigen (PSMA): studies in nude mice. The Prostate, 2004, Feb-01, Volume: 58, Issue:2 Topics: Animals; Antibodies, Monoclonal; Antigens, Surface; Chelating Agents; Glutamate Carboxypeptidase II; Heterocyclic Compounds, 1-Ring; Humans; Iodine Radioisotopes; Male; Maximum Tolerated Dose; Mice; Mice, Inbred BALB C; Mice, Nude; Prostatic Neoplasms; Radioimmunotherapy; Random Allocation; Survival Analysis; Transplantation, Heterologous; Yttrium Radioisotopes	2004
Synthesis and evaluation of bombesin derivatives on the basis of pan-bombesin peptides labeled with indium-111, lutetium-177, and yttrium-90 for targeting bombesin receptor-expressing tumors. Cancer research, 2004, Sep-15, Volume: 64, Issue:18 Topics: Animals; Bombesin; Drug Stability; Humans; Indium Radioisotopes; Isotope Labeling; Lutetium; Male; Pancreatic Neoplasms; Prostatic Neoplasms; Radioisotopes; Radionuclide Imaging; Radiopharmaceuticals; Rats; Receptors, Bombesin; Tissue Distribution; Yttrium Radioisotopes	2004
Determination of immunoreactive fraction of radiolabeled monoclonal antibodies: what is an appropriate method? Cancer biotherapy & radiopharmaceuticals, 2004, Volume: 19, Issue:6 Topics: Animals; Antibodies, Monoclonal; Antigen-Antibody Reactions; Antigens, Neoplasm; Antigens, Surface; Binding Sites, Antibody; Glutamate Carboxypeptidase II; Indium Radioisotopes; Male; Models, Theoretical; Prostatic Neoplasms; Radioimmunodetection; Radioimmunotherapy; Radiopharmaceuticals; Tumor Cells, Cultured; Yttrium Radioisotopes	2004
Mass spectral analyses of labile DOTA-NHS and heterogeneity determination of DOTA or DM1 conjugated anti-PSMA antibody for prostate cancer therapy. Journal of pharmaceutical sciences, 2005, Volume: 94, Issue:4 Topics: Antibodies; Antineoplastic Agents, Phytogenic; Chromatography, High Pressure Liquid; Heterocyclic Compounds, 1-Ring; Humans; Immunotherapy; Immunotoxins; Male; Mass Spectrometry; Matrix Metalloproteinases; Maytansine; Molecular Weight; Pharmaceutical Solutions; Prostate-Specific Antigen; Prostatic Neoplasms; Quality Control; Reference Standards; Reproducibility of Results; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Succinimides; Yttrium Radioisotopes	2005
Radioimmunotherapy of prostate cancer: does tumor size matter? Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Jul-20, Volume: 23, Issue:21 Topics: Antibodies, Monoclonal; Humans; Lutetium; Male; Prostatic Neoplasms; Radioimmunotherapy; Radioisotopes; Yttrium Radioisotopes	2005
Imaging with radiolabelled monoclonal antibody (MUJ591) to prostate-specific membrane antigen in staging of clinically localized prostatic carcinoma: comparison with clinical, surgical and histological staging. BJU international, 2005, Volume: 95, Issue:9 Topics: Aged; Antibodies, Monoclonal; Antigens, Surface; Glutamate Carboxypeptidase II; Humans; Iodine Radioisotopes; Male; Middle Aged; Neoplasm Staging; Prostatic Neoplasms; Radionuclide Imaging; Radiopharmaceuticals; Technetium; Yttrium Radioisotopes	2005
Identification of a novel prostate tumor target, mindin/RG-1, for antibody-based radiotherapy of prostate cancer. Cancer research, 2005, Sep-15, Volume: 65, Issue:18 Topics: Amino Acid Sequence; Animals; Antibodies, Monoclonal; Antibody Specificity; Bone Neoplasms; CHO Cells; Cricetinae; Dose-Response Relationship, Immunologic; Extracellular Matrix Proteins; Humans; Immunotoxins; Isothiocyanates; Male; Molecular Sequence Data; Pentetic Acid; Positron-Emission Tomography; Prostatic Neoplasms; Radioimmunotherapy; RNA, Messenger; Tissue Distribution; Xenograft Model Antitumor Assays; Yttrium Radioisotopes	2005
Enhancement of the therapeutic index: from nonmyeloablative and myeloablative toward pretargeted radioimmunotherapy for metastatic prostate cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Oct-01, Volume: 11, Issue:19 Pt 2 Topics: Antibodies, Monoclonal; Antigens; Antigens, Neoplasm; Bone Marrow; Cathepsins; Combined Modality Therapy; Electrophoresis, Polyacrylamide Gel; Epitopes; Glycoproteins; Humans; Immunohistochemistry; Male; Maleimides; Maximum Tolerated Dose; Models, Chemical; Mucin-1; Mucins; Neoplasm Metastasis; Paclitaxel; Peptide Library; Peptides; Polyethylene Glycols; Prostatic Neoplasms; Protein Binding; Radioimmunotherapy; Radiometry; Yttrium Radioisotopes	2005
Polymer-peptide conjugates for angiogenesis targeted tumor radiotherapy. Nuclear medicine and biology, 2006, Volume: 33, Issue:1 Topics: Animals; Drug Carriers; Humans; Male; Metabolic Clearance Rate; Methacrylates; Mice; Mice, SCID; Neovascularization, Pathologic; Oligopeptides; Organ Specificity; Prostatic Neoplasms; Radiopharmaceuticals; Radiotherapy; Technetium; Tissue Distribution; Treatment Outcome; Yttrium Radioisotopes	2006
Comparison of normal tissue pharmacokinetics with 111In/90Y monoclonal antibody m170 for breast and prostate cancer. International journal of radiation oncology, biology, physics, 2006, Nov-15, Volume: 66, Issue:4 Topics: Antibodies, Monoclonal; Breast Neoplasms; Female; Humans; Indium Radioisotopes; Male; Metabolic Clearance Rate; Organ Specificity; Prostatic Neoplasms; Radiopharmaceuticals; Tissue Distribution; Yttrium Radioisotopes	2006
[Treatment of pains from bone metastases with 90Y (author's transl)]. Nuklearmedizin. Nuclear medicine, 1981, Volume: 20, Issue:5 Topics: Bone Neoplasms; Breast Neoplasms; Female; Half-Life; Humans; Lung Neoplasms; Male; Melanoma; Pain, Intractable; Palliative Care; Prostatic Neoplasms; Radiotherapy Dosage; Stomach Neoplasms; Yttrium Radioisotopes	1981
[Interstitial radiotherapy]. Wiener medizinische Wochenschrift (1946), 1983, Jun-30, Volume: 133, Issue:12 Topics: Brachytherapy; Breast Neoplasms; Cobalt Radioisotopes; Gold Radioisotopes; Head and Neck Neoplasms; Humans; Iodine Radioisotopes; Iridium; Male; Mouth Neoplasms; Pituitary Neoplasms; Prostatic Neoplasms; Radioisotope Teletherapy; Radioisotopes; Tantalum; Urinary Bladder Neoplasms; Yttrium Radioisotopes	1983
Radiation doses of yttrium-90 citrate and yttrium-90 EDTMP as determined via analogous yttrium-86 complexes and positron emission tomography. European journal of nuclear medicine, 1996, Volume: 23, Issue:8 Topics: Aged; Aged, 80 and over; Bone Marrow; Bone Neoplasms; Citrates; Humans; Male; Middle Aged; Organometallic Compounds; Organophosphonates; Palliative Care; Prostatic Neoplasms; Radiotherapy Dosage; Tomography, Emission-Computed; Yttrium Radioisotopes	1996
DOTA-lanreotide: a novel somatostatin analog for tumor diagnosis and therapy. Endocrinology, 1999, Volume: 140, Issue:11 Topics: Adenocarcinoma; Animals; Breast Neoplasms; Carcinoid Tumor; Cell Membrane; Colonic Neoplasms; Heterocyclic Compounds, 1-Ring; Humans; Indium Radioisotopes; Liver Neoplasms; Lymphoma, Non-Hodgkin; Male; Neoplasms; Pancreatic Neoplasms; Peptides, Cyclic; Prostatic Neoplasms; Rats; Rats, Sprague-Dawley; Thyroid Neoplasms; Tissue Distribution; Tumor Cells, Cultured; Yttrium Radioisotopes	1999
Efficacy and toxicity of radioimmunotherapy with (90)Y-DOTA-peptide-ChL6 for PC3-tumored mice. The Prostate, 2000, Aug-01, Volume: 44, Issue:3 Topics: Animals; Antibodies, Monoclonal; Body Weight; Dose-Response Relationship, Radiation; Female; Heterocyclic Compounds; Humans; Leukocyte Count; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Oligopeptides; Platelet Count; Prostatic Neoplasms; Radioimmunotherapy; Radiopharmaceuticals; Specific Pathogen-Free Organisms; Tumor Cells, Cultured; Whole-Body Counting; Yttrium; Yttrium Radioisotopes	2000
The sublabial transseptal transsphenoidal approach to the hypophysis. The Laryngoscope, 1978, Volume: 88, Issue:7 Pt 2 Sup Topics: Breast Neoplasms; Cryosurgery; Diabetic Retinopathy; Gold Radioisotopes; Headache; Humans; Hypophysectomy; Male; Pituitary Gland; Pituitary Irradiation; Pituitary Neoplasms; Prostatic Neoplasms; Sella Turcica; Skull; Sphenoid Sinus; Surgical Instruments; Ultrasonics; Yttrium Radioisotopes	1978
[Scintigraphic use of 87Y during 90Y therapy of bone metastases]. Nuklearmedizin. Nuclear medicine, 1992, Volume: 31, Issue:2 Topics: Aged; Bone Neoplasms; Carcinoma, Bronchogenic; Humans; Lung Neoplasms; Male; Middle Aged; Prostatic Neoplasms; Radionuclide Imaging; Stomach Neoplasms; Yttrium Radioisotopes	1992